'I think therefore I am': improving cognition

被引:2
作者
Ritchie, Karen [1 ]
Portet, Florence [1 ]
机构
[1] La Colombiere Hosp, INSERM Unit E361, Montpellier, France
关键词
cognitive dysfunction; decision-making; mild cognitive impairment; therapy;
D O I
10.1097/01.yco.0000245744.60631.84
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of review in the absence of a specific treatment for dementia, the effective management of cognitive symptoms is a clinical priority. Recent findings Although some differences have been observed in the profile of cognitive complaints observed in subtypes of dementia, there is increasing recognition of common, interacting neurobiological causes suggesting the need to seek a, common treatment applicable to all causes of cognitive deterioration. There also exists increasing interest in,intervening at the level of minor cognitive dysfunction by i reducing risk factors for. subclinical states. Summary Pharmacological treatment of cognitive disorder is beneficial but has only temporary benefit for a subgroup of patients. Pharmacogenetics may have an important future role to play in deciding which patients may best benefit from the treatment. Low side effect therapies such as, cognitive therapy and acupuncture show some benefits but their utility in combination With pharmacotherapies remains to be demonstrated. Prevention of milder forms of cognitive disorder by controlling risk factors such as, hypertension and diabetes-may reduce rates of more severe cognitive degeneration. Persons with cognitive dysfunction are commonly excluded from making decisions about the implementation of cognition-enhancing treatments although they wish to do so:
引用
收藏
页码:570 / 574
页数:5
相关论文
共 37 条
[1]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[2]   Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study [J].
Ancelin, ML ;
Artero, S ;
Portet, F ;
Dupuy, AM ;
Touchon, J ;
Ritchie, K .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7539) :455-458
[3]   Lifelong endocrine fluctuations and related cognitive disorders [J].
Ancelin, ML ;
Ritchie, K .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (32) :4229-4252
[4]  
[Anonymous], 2003, COCHRANE DB SYST REV
[5]  
Areosa S. A., 2006, COCHRANE DB SYST REV
[6]   Risk of dementia in diabetes mellitus: a systematic review [J].
Biessels, GJ ;
Staekenborg, S ;
Brunner, E ;
Brayne, C ;
Scheltens, P .
LANCET NEUROLOGY, 2006, 5 (01) :64-74
[7]  
Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub2, 10.1002/14651858.CD001190.pub3]
[8]   Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease [J].
Bullock, R ;
Bergman, H ;
Touchon, J ;
Gambina, G ;
He, YS ;
Nagel, J ;
Lane, R .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (03) :483-494
[9]   Pharmacogenomics and therapeutic prospects in Alzheimer's disease [J].
Cacabelos, R .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (12) :1967-1987
[10]   Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment [J].
DeKosky, ST ;
Ikonomovic, MD ;
Styren, SD ;
Beckett, L ;
Wisniewski, S ;
Bennett, DA ;
Cochran, EJ ;
Kordower, JH ;
Mufson, EJ .
ANNALS OF NEUROLOGY, 2002, 51 (02) :145-155